A Phase 1, Multicenter, Open-label, Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion Following Autologous Stem Cell Transplant for Multiple Myeloma

Trial Profile

A Phase 1, Multicenter, Open-label, Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion Following Autologous Stem Cell Transplant for Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Aldesleukin (Primary) ; PNK 007 (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 13 Feb 2017 Planned number of patients changed from 34 to 40.
    • 13 Feb 2017 Planned End Date changed from 1 Aug 2019 to 1 Nov 2018.
    • 13 Feb 2017 Planned primary completion date changed from 1 May 2019 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top